Analogous solvent‐front mutations have also been identified in other tyrosine kinases and confer to TKI‐resistance, such as RET‐G810 solvent mutations after selpercatinib treatment in NSCLC patients,84, 85EGFR‐G706S/R mutation following osimertinib treatment in NSCLC patients,89TRKA‐G595R and TRKA‐G667C mutations after entrectinib treatment in colorectal cancer patients.86 The gene discussed is RET; the disease is non-small cell lung carcinoma.